Denali Corporate Deck_JPM_January 2023.pdf

《Denali Corporate Deck_JPM_January 2023.pdf》由会员分享，可在线阅读，更多相关《Denali Corporate Deck_JPM_January 2023.pdf（27页珍藏版）》请在三个皮匠报告上搜索。

1、Corporate OverviewJanuary 2023DisclaimersForward-Looking Statements.This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.These forward-looking statements do not relate strictly to historical or current facts and they may be

2、accompanied by such words as“anticipate,”“believe,”“could,”“estimate,”“expected,”“forecast,”“intend,”“may,”“plan,”“potential,”“possible,”future,“will”and other words and terms of similar meaning.All statements other than statements of historical facts contained in this presentation,including,without

3、 limitation,statements regarding future results of operations and financial position of Denali Therapeutics Inc.(“Denali”or the“Company”);Denalis business strategy and business plans,expected progress and expansion,and expected key milestones for Denalis therapeutic portfolio in 2023 and beyond;Dena

4、lis ability to execute on its tailored commercial strategies and accelerate commercial launch readiness in key markets,including the US and China;expectations relating to the potential for Denalis product candidates to treat various neurodegenerative diseases including MPSI,MPS II(Hunter Syndrome),M

5、PS IIIA(Sanfilippo Syndrome),ALS,MS,PD,AD,FTD-GRN,CLE,UC,and related peripheral inflammatory diseases,as well as expectations and timelines relating to the continued progress and potential of its small molecule programs;planned preclinical studies and clinical trials and the expectations regarding t

6、he timing and availability of results and data from such studies and trials;plans,timelines,expectations,and current and future therapeutic and commercial opportunities related to Denalis Transport Vehicle(TV)platform,including its Enzyme Transport Vehicle(ETV),Antibody Transport Vehicle(ATV),Protei